Article
Oncology
Philip Q. Ding, Flora Au, Winson Y. Cheung, Steven J. Heitman, Richard Lee-Ying
Summary: Up to 65% of patients with metastatic colorectal cancer experience disease recurrence following curative-intent metastasectomy. There is little evidence for the use of surveillance in metastatic colorectal cancer and no clear consensus on the best strategy. Our economic analysis demonstrates that surveillance with clinic visits and investigations every 12 months for 5 years would be cost-effective in a Canadian context.
Article
Pharmacology & Pharmacy
Meiyu Wu, Shuxia Qin, Liting Wang, Chongqing Tan, Ye Peng, Xiaohui Zeng, Xia Luo, Lidan Yi, Xiaomin Wan
Summary: This study evaluated the cost-effectiveness of pembrolizumab plus chemotherapy as first-line therapy for advanced oesophageal cancer from the perspective of the Chinese healthcare system. The results showed that this treatment approach was not cost-effective compared to placebo plus chemotherapy.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Public, Environmental & Occupational Health
Nan Yang, Han Yang, Jeff Jianfei Guo, Ming Hu, Sheyu Li
Summary: This study found that ultrasound screening for thyroid cancer did not have a clear advantage in terms of cost-effectiveness compared with non-screening. It is essential to optimize thyroid screening strategies for specific populations.
FRONTIERS IN PUBLIC HEALTH
(2021)
Article
Oncology
Vivek S. Chaudhari, Amalia M. Issa
Summary: This study compared the cost-effectiveness of marketed genomic tests in predicting stage II colorectal cancer patients, with the Immunoscore assay appearing to be a dominant strategy in terms of cost saving and providing useful information for policymakers.
ANNALS OF TRANSLATIONAL MEDICINE
(2022)
Article
Pharmacology & Pharmacy
Gengwei Huo, Wenjie Liu, Shuo Kang, Peng Chen
Summary: The combination therapy of toripalimab with chemotherapy has been found to be cost-effective for previously untreated advanced non-small cell lung cancer patients, particularly those with squamous NSCLC, from the perspective of the Chinese healthcare system. These findings provide valuable evidence for clinicians in making treatment decisions in general clinical practice.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Public, Environmental & Occupational Health
Zhuo-miao Ye, Zhe Xu, Huan Li, Qian Li
Summary: The cost effectiveness of durvalumab plus chemotherapy compared to placebo plus chemotherapy for the first-line treatment of biliary tract cancer was assessed from the perspective of US and Chinese payers. Results showed that durvalumab in combination with chemotherapy is not a cost-effective option for the treatment of BTC in both countries.
FRONTIERS IN PUBLIC HEALTH
(2023)
Article
Oncology
Huiling Piao, Meiyu Wu, Shuxia Qin, Zhiyao Tang, Guangliang Zhou, Xiaomin Wan, Xiaocong Zuo
Summary: The GOG 281/LOGS trial demonstrated that trametinib improves progression-free survival in patients with recurrent LGSOC compared to standard of care. This study aimed to evaluate the cost-effectiveness of trametinib versus standard of care in the US payer perspective. The results suggest that from the US payer perspective, trametinib is not cost-effective for patients with recurrent LGSOC. Rating: 7/10.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Pharmacology & Pharmacy
Xiaomin Wan, Xiaohui Zeng, Liubao Peng, Ye Peng, Qiao Liu, Lidan Yi, Xia Luo, Qijian Deng, Chongqing Tan
Summary: The study suggests that nivolumab plus ipilimumab may be more cost-effective compared to chemotherapy, especially at a WTP threshold of $100,000/QALY to $150,000/QALY. Body weight and overall survival hazard ratio are key variables influencing the cost-effectiveness ratio.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Immunology
Giuseppe Santoli, Mario Cesare Nurchis, Giovanna Elisa Calabro, Gianfranco Damiani
Summary: SARS-CoV-2 vaccination has proven highly effective in preventing COVID-19, reducing global deaths and hospitalizations. While vaccine distribution remains unequal, it is crucial to organize mass vaccination campaigns worldwide to control the spread of the virus. This systematic review confirms that COVID-19 vaccination campaigns are cost-effective and sustainable public health measures in fighting the pandemic.
Article
Pharmacology & Pharmacy
Tianyu Feng, Zhou Zheng, Shang Gao, Jiaying Xu, Pen Cao, Huanhuan Jia, Xihe Yu
Summary: This study investigated the cost-effectiveness of low-dose rivaroxaban plus aspirin versus aspirin alone in patients with stable cardiovascular diseases in China. The results showed that low-dose rivaroxaban combined with aspirin therapy may be cost-effective in the secondary prevention of stable cardiovascular disease in patients.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Surgery
Amelia J. Hessheimer, Ana Magdalena Vargas-Martinez, Marta Trapero-Bertran, Miquel Navasa, Constantino Fondevila
Summary: This study evaluated the cost-effectiveness and utility of posttransplant hepatocellular carcinoma (HCC) surveillance compared to standard follow-up. Although surveillance slightly improves survival and quality of life, it also increases costs and does not appear to be cost-effective in this setting.
Article
Pharmacology & Pharmacy
Zhuo-Miao Ye, Zhe Xu, Fan-Yuan Zeng, Zi-Qing Tang, Qin Zhou
Summary: This study evaluated the cost-effectiveness of sintilimab plus chemotherapy compared to chemotherapy alone in treating patients with esophageal cancer, and found that it is more cost-effective in Chinese patients.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Zhuo-Miao Ye, Zhe Xu, Hao-Lun Wang, Ying-Yuan Wang, Ze-Chang Chen, Qin Zhou, Xiang-Ping Li, Ying-Ying Zhang
Summary: This study simulated the 10-year survival rate of patients with advanced esophageal cancer using a Markov model and evaluated the economics of Pembrolizumab plus chemotherapy. The results showed that Pembrolizumab plus chemotherapy is not a cost-effective option, regardless of PD-L1 expression status.
Review
Gastroenterology & Hepatology
Le Wang, Chengcheng Liu, Youqing Wang, Lingbin Du
Summary: Tailored screening for colorectal cancer based on individual risk factors shows potential cost-effectiveness, but the current economic evidence is insufficient to support its replacement for age-based screening.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Immunology
Coralei E. Neighbors, Evan R. Myers, Nayani P. Weerasinghe, Gaya B. Wijayaratne, Champica K. Bodinayake, Ajith Nagahawatte, L. Gayani Tillekeratne, Christopher W. Woods
Summary: Influenza vaccination is cost-effective for the Sri Lankan population, reducing cases, hospitalizations, and deaths caused by influenza. The most influential factors are vaccine coverage and effectiveness in different age groups. Providing influenza vaccines is highly cost-effective compared to not vaccinating. However, more large-scale national studies are needed to improve data and assess the impact of vaccination implementation.